gamma-secretases: from cell biology to therapeutic strategies (Q37686625)

22 August 2017

1 reference

title

gamma-secretases: from cell biology to therapeutic strategies (English)

1 reference

22 August 2017

1 reference

2

Bart De Strooper

1 reference

22 August 2017

Bruno A Bergmans

1

1 reference

PubMed ID

20129170

22 August 2017

language of work or name

1 reference

1 February 2010

1 reference

22 August 2017

1 reference

22 August 2017

9

1 reference

22 August 2017

2

1 reference

22 August 2017

215-226

1 reference

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Candidate gene for the chromosome 1 familial Alzheimer's disease locus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Estimation of the Genetic Contribution of Presenilin-1 and -2 Mutations in a Population-Based Study of Presenile Alzheimer Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Early onset familial Alzheimer's disease: Mutation frequency in 31 families.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Incidence and risk of dementia. The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilin mutations in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilin-dependent "gamma-secretase" processing of deleted in colorectal cancer (DCC)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Deficiency of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Gamma-secretase: proteasome of the membrane?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Control of peripheral nerve myelination by the beta-secretase BACE1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A Novel Missense Mutation in the Transmembrane Domain of Neuregulin 1 is Associated with Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Neuregulin 1 and susceptibility to schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Gamma-secretase modulators: hopes and setbacks for the future of Alzheimer's treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

The gamma-secretase complex: membrane-embedded proteolytic ensemble

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilin: running with scissors in the membrane

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilin is required for activity and nuclear access of Notch in Drosophila

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A common enzyme connects notch signaling and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Notch signalling in vertebrate neural development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Partial loss of presenilins causes seborrheic keratosis and autoimmune disease in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilins are essential for regulating neurotransmitter release

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A specific amyloid-beta protein assembly in the brain impairs memory

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Late onset familial Alzheimer's disease: novel presenilin 2 mutation and PS1 E318G polymorphism.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Identification of gamma-secretase inhibitor potency determinants on presenilin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Very early onset AD with a de novo mutation in the presenilin 1 gene (Met 233 Leu)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Variant Alzheimer's disease with spastic paraparesis: clinical characterization.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A pathogenic presenilin-1 deletion causes abberrant Abeta 42 production in the absence of congophilic amyloid plaques

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Early onset familial Alzheimer Disease with spastic paraparesis, dysarthria, and seizures and N135S mutation in PSEN1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A novel presenilin 1 mutation (Y154N) in a patient with early onset Alzheimer's disease with spastic paraparesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Very early onset Alzheimer's disease with spastic paraparesis associated with a novel presenilin 1 mutation (Phe237Ile).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A novel presenilin 1 mutation (V261L) associated with presenile Alzheimer's disease and spastic paraparesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Spastic paraparesis and atypical dementia caused by PSEN1 mutation (P264L), responsible for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Molecular evidence of presenilin 1 mutation in familial early onset dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Pure spastic paraparesis associated with a novel presenilin 1 R278K mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A presenilin 1 mutation (Arg278Ser) associated with early onset Alzheimer's disease and spastic paraparesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

PS1 Alzheimer's disease family with spastic paraplegia: the search for a gene modifier.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Alzheimer's disease with spastic paresis and cotton wool type plaques

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Dementia, pyramidal system involvement, and leukoencephalopathy with a presenilin 1 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Alzheimer's disease with spastic paraparesis and 'cotton wool' plaques: two pedigrees with PS-1 exon 9 deletions.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Variable phenotype of Alzheimer's disease with spastic paraparesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Novel presenilin-1 mutation with widespread cortical amyloid deposition but limited cerebral amyloid angiopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Invited article: the Alzheimer disease-frontotemporal lobar degeneration spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A novel PSEN2 mutation associated with a peculiar phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Targeting the Notch1 and mTOR pathways in a mouse T-ALL model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Notch signaling contributes to the pathogenesis of human osteosarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Gleevec inhibits β-amyloid production but not Notch cleavage

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Substrate-targeting gamma-secretase modulators

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Indomethacin for the treatment of Alzheimer's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Disease-modifying therapies in Alzheimer's disease: how far have we come?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Selective inhibition of Abeta42 production by NSAID R-enantiomers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Coordinated and widespread expression of gamma-secretase in vivo: evidence for size and molecular heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Identification of distinct gamma-secretase complexes with different APH-1 variants

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

The role of presenilin cofactors in the gamma-secretase complex

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

APH-1a is the principal mammalian APH-1 isoform present in gamma-secretase complexes during embryonic development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970332-1

7 January 2021

10.1016/S1474-4422(09)70332-1

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20129170